Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03756896 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 28, 2018
Last Update Posted : March 8, 2024
|
Sponsor:
Emory University
Collaborators:
Amgen
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Ajay Nooka, Emory University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | March 31, 2025 |
| Estimated Study Completion Date : | March 31, 2026 |